A serious, life threatening rare neurologic disease characterized by a sudden rupture of an intracranial aneurysm into the subarachnoid space. It usually presents with a sudden, severe, excruciating h...
Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding acquired aneurysmal subarachnoid hemorrhage is largely due to its rarity, affecting only a small number of individuals globally. This low prevalence results in fewer systematic clinical studies and a lack of comprehensive data on genetic factors and phenotypic expressions. As a result, our understanding of this condition is still evolving, and ongoing research is essential to improve patient outcomes.
To navigate your care effectively, consider consulting a neurologist with expertise in cerebrovascular disorders, specifically those who have experience with aneurysmal conditions. While no specific patient organizations are identified for this condition, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, participating in a natural history study or registry, if available, could contribute to a better understanding of this condition and help connect you with others affected.
Currently, there are several orphan drugs designated for the treatment of acquired aneurysmal subarachnoid hemorrhage, including nimodipine, which is FDA-approved. Other drugs in development include various compounds aimed at addressing the condition's complications. Unfortunately, there is no available clinical trial data at this time. For updates on research and potential trials, you can search ClinicalTrials.gov for ongoing studies related to this condition.
Actionable guidance for navigating care for acquired aneurysmal subarachnoid hemorrhage
To navigate your care effectively, consider consulting a neurologist with expertise in cerebrovascular disorders, specifically those who have experience with aneurysmal conditions. While no specific patient organizations are identified for this condition, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, participating in a natural history study or registry, if available, could contribute to a better understanding of this condition and help connect you with others affected.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding acquired aneurysmal subarachnoid hemorrhage is largely due to its rarity, affecting only a small number of individuals globally. This low prevalence results in fewer systematic clinical studies and a lack of comprehensive data on genetic factors and phenotypic expressions. As a result, our understanding of this condition is still evolving, and ongoing research is essential to improve patient outcomes.
To navigate your care effectively, consider consulting a neurologist with expertise in cerebrovascular disorders, specifically those who have experience with aneurysmal conditions. While no specific patient organizations are identified for this condition, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, participating in a natural history study or registry, if available, could contribute to a better understanding of this condition and help connect you with others affected.
Currently, there are several orphan drugs designated for the treatment of acquired aneurysmal subarachnoid hemorrhage, including nimodipine, which is FDA-approved. Other drugs in development include various compounds aimed at addressing the condition's complications. Unfortunately, there is no available clinical trial data at this time. For updates on research and potential trials, you can search ClinicalTrials.gov for ongoing studies related to this condition.
Actionable guidance for navigating care for acquired aneurysmal subarachnoid hemorrhage
To navigate your care effectively, consider consulting a neurologist with expertise in cerebrovascular disorders, specifically those who have experience with aneurysmal conditions. While no specific patient organizations are identified for this condition, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, participating in a natural history study or registry, if available, could contribute to a better understanding of this condition and help connect you with others affected.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding acquired aneurysmal subarachnoid hemorrhage is largely due to its rarity, affecting only a small number of individuals globally. This low prevalence results in fewer systematic clinical studies and a lack of comprehensive data on genetic factors and phenotypic expressions. As a result, our understanding of this condition is still evolving, and ongoing research is essential to improve patient outcomes.
To navigate your care effectively, consider consulting a neurologist with expertise in cerebrovascular disorders, specifically those who have experience with aneurysmal conditions. While no specific patient organizations are identified for this condition, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, participating in a natural history study or registry, if available, could contribute to a better understanding of this condition and help connect you with others affected.
Currently, there are several orphan drugs designated for the treatment of acquired aneurysmal subarachnoid hemorrhage, including nimodipine, which is FDA-approved. Other drugs in development include various compounds aimed at addressing the condition's complications. Unfortunately, there is no available clinical trial data at this time. For updates on research and potential trials, you can search ClinicalTrials.gov for ongoing studies related to this condition.
Actionable guidance for navigating care for acquired aneurysmal subarachnoid hemorrhage
To navigate your care effectively, consider consulting a neurologist with expertise in cerebrovascular disorders, specifically those who have experience with aneurysmal conditions. While no specific patient organizations are identified for this condition, resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information. Additionally, participating in a natural history study or registry, if available, could contribute to a better understanding of this condition and help connect you with others affected.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 1 company has orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.